Hogan Lovells advised Collegium Pharmaceutical in agreement to acquire Ironshore Therapeutics

The acquisition of Ironshore will represent a significant milestone in advancing Collegium’s mission of building a leading, diversified specialty pharmaceutical company by expanding its business beyond pain management and establishing a commercial presence in neurology via the large and growing Attention Deficit Hyperactivity Disorder (ADHD) market.

Ironshore is a privately held, pharmaceutical company that markets and distributes Jornay PM® (methylphenidate HCl), a central nervous system stimulant prescription medicine for the treatment of ADHD in people six years of age and older, and the only stimulant medication that is dosed in the evening.

More information and transaction details can be found here.

The Hogan Lovells team was led by partner Jessica Bisignano (Philadelphia), senior associate Shaida Mirmazaheri (Boston), and associate Kayvon Paul (Philadelphia).